Arrowhead signs Novartis license for ARO-SNCA with $200 million upfront payment
Arrowhead Pharmaceuticals entered an exclusive license and collaboration agreement with Novartis for ARO-SNCA, a preclinical RNA interference therapy for Parkinson's Disease and other synucleinopathies, plus additional collaboration targets. Arrowhead will receive a $200 million upfront payment upon closing and is eligible for up to $2 billion in milestones and tiered royalties up to the low double digits on net sales, but the deal remains subject to closing conditions including the Hart-Scott-Rodino waiting period.
Key points
- Upfront payment of $200 million to Arrowhead, payable upon closing
- Eligible for up to $2 billion in development, regulatory and sales milestones, plus royalties up to the low double digits
- Novartis takes sole control of clinical development, manufacturing and commercialization after Arrowhead completes preclinical work
- Transaction expected to close in the second half of 2025, subject to Hart-Scott-Rodino and other customary conditions
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.